PT-141
Effect Profile
How PT-141 scores across 8 body systems
20
/ 80 total
Top strengths
Purrptide digest
PT-141 (bremelanotide) is the cleaned-up, FDA-approved descendant of Melanotan II's accidental libido discovery — minus the tanning effect and minus the unapproved status. It's marketed as Vyleesi specifically for hypoactive sexual desire disorder in premenopausal women, working through the central nervous system rather than blood flow like Viagra. Off-label use in men has grown steadily, since the mechanism — melanocortin receptor activation affecting libido centrally — isn't actually sex-specific.
What this means for you
An FDA-approved option exists if libido is the specific issue, working through a completely different pathway than erectile-dysfunction drugs.
Approved for women, but the central melanocortin mechanism isn't sex-specific — off-label male use has real mechanistic grounding.
A central nervous system approach to sexual dysfunction, distinct from the vascular mechanism of PDE5 inhibitors like sildenafil.
An approved drug with an expanding off-label use case is a clean, low-risk commercial story already in motion.
For the nerds
Bremelanotide for Treatment of Hypoactive Sexual Desire Disorder
Obstetrics & Gynecology · DOI: 10.1097/AOG.0000000000003500
Read full paper on PubMed →